Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Journal: The New England journal of medicine
Published: November 08, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: August 24, 2019
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Journal: The New England journal of medicine
Published: October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Journal: The New England journal of medicine
Published: October 19, 2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Journal: The Lancet. Respiratory medicine
Published: March 15, 2018
The impact of migration on cardiovascular diseases.
Journal: International journal of cardiology
Published: November 18, 2017
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Journal: The New England journal of medicine
Published: November 04, 2017
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Journal: The New England journal of medicine
Published: November 04, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026